Our results not only provide a basis for establishing HNRNPA2B1-targeted molecular therapy in pancreatic cancer but also enrich the current understanding of HNRNPA2B1’s regulation of EMT and its potential signalling pathway. This evidence concerns the gene HNRNPA2B1 and familial pancreatic carcinoma.